Beyond ozempic: GLP-1s and the next wave of anti-obesity drugs
Saloni Paliwal, Co-founder, Voy India highlights the evolution of GLP-1 therapies beyond Ozempic, examining the science, market…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
GLP-1 drugs
Navigating legal and regulatory landscape of GLP-1 drugs in India
India is currently facing a growing public health issue, with recent data showing that nearly a quarter of the adult population is…
DCGI launches nationwide drive to curb illegal sale of GLP-1 drugs
In a significant move to uphold ethical pharma practices and safeguard public health, the Drugs Controller General of India has…
India’s upcoming semaglutide boom: A turning point for GLP‑1 drugs, pricing and patient access
With semaglutide’s Indian patent set to expire on March 20, 2026, domestic drugmakers are preparing to enter the GLP‑1 market,…
WHO issues warnings on fake copies of Novo Nordisk’s weight-loss drugs
The warnings were issued on fake drugs claiming to contain the active ingredient found in Novo Nordisk's diabetes drug Ozempic…